Glenmark Pharmaceuticals Limited (GLENMARK): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Glenmark Pharmaceuticals Limited, explained in plain English.

• ▪Glenmark Pharmaceuticals Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪GLENMARK closed at ₹2,481.80 on 5 November 2026.
• ▪Over the past year the shares are up 37.1%, trading between ₹1,801.40 and ₹2,542.20.
• ▪Reported fundamentals show a net margin of 10.14%, debt to equity of 5.65.
• ▪Our transparent MaxGrade checklist scores it B (71/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 28.09% with a maximum drawdown of -13.85% and a beta of 0.88 against NIFTY 50.
• ▪Recent coverage: Glenmark Pharma Q2 revenue falls 30% to ₹4,247 crore, profit down 57%

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 5 Nov 2026. Market closed.